Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

BNCT and IG-IMRT for Recurrent Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02004795
Recruitment Status : Unknown
Verified November 2013 by Taipei Veterans General Hospital, Taiwan.
Recruitment status was:  Recruiting
First Posted : December 9, 2013
Last Update Posted : December 9, 2013
Sponsor:
Collaborator:
National Tsing Hua University,Taiwan
Information provided by (Responsible Party):
Taipei Veterans General Hospital, Taiwan

Brief Summary:

This is a boron neutron capture therapy (BNCT) combined with image-guided intensity modulation radiotherapy (IG-IMRT) for patients with previously irradiated and locally recurrent head and neck cancer. The primary end points are treatment toxicities and response rate. The secondary endpoints are time to tumor progression, progression-free survival, overall survival and change quality of life.

Head and neck(H & N) carcinomas that recur locally after conventional irradiation pose a therapeutic challenge. Boron neutron capture therapy (BNCT) is based on the nuclear capture reaction that occurs when non-radioactive boron is irradiated with neutrons of thermal energy to yield high energy alpha particles and recoiling lithium nuclei. The effect of alpha and 7Li is primarily limited to boron-containing cells. Preferential uptake of boron into cancerous tissue is achieved using boron carriers such as a derivative of phenylalanine, boronophenylalanine (BPA). After administration of BPA by intravenous infusion, the tumor site is irradiated with neutrons, the source of which is currently a nuclear reactor, like the Tsing Hua Open-Pool Reactor (THOR), a 2MW research reactor at National Tsing Hua University (NTHU) in Taiwan. Since it is a target radiotherapy, low complication rate after BNCT can be obtained. However, further local recurrence after BNCT for recurrent H & N cancer was reported in several publications.

Image-guided radiation therapy (IGRT) is the process of frequent two and three-dimensional imaging, during a course of radiation treatment, used to direct radiation therapy utilizing the imaging coordinates of the approved radiation treatment plan. IGRT such as Cone-Beam CT (CBCT) using an On-Board Imager (OBI) enhance delivery and further improve outcomes as the treatments create a higher level of precision. By combining BNCT and IG-IMRT, we expect to procure high control rate of recurrent H & N cancer with acceptable toxicity. This study will be the first BNCT plus IG-IMRT trial to treat head and neck cancer in Taiwan.


Condition or disease Intervention/treatment Phase
Head and Neck Cancer Recurrence Radiation: BNCT + IG-IMRT Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of Boron Neutron Capture Therapy (BNCT) Combined With Image-guided Intensity Modulated Radiotherapy (IG-IMRT) for Locally Recurrent Head and Neck Cancer
Study Start Date : November 2013
Estimated Primary Completion Date : November 2016
Estimated Study Completion Date : November 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BNCT+ IG-IMRT
single arm
Radiation: BNCT + IG-IMRT
Single faction of BNCT (20 Gy) plus IG-IMRT (40 Gy/20 fractions)




Primary Outcome Measures :
  1. treatment toxicities [ Time Frame: two years after combined treatment ]
    To evaluate both acute and late toxicities after combined BNCT and IG-IMRT

  2. response rate [ Time Frame: Three months after combined treatment ]
    including complete and partial response rate after BNCT+IG-IMRT


Secondary Outcome Measures :
  1. Time to tumor progression [ Time Frame: two years ]
    defined from the date of BNCT to the date of tumor progression by clinical evaluation.

  2. Progression-free survival [ Time Frame: two years ]
    calculated from the date of BNCT to the date of cancer progression either locally or distally or to death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • For BNCT:

    1. Patients with locoregionally recurrent, histologically proved malignancy of the head and neck, including primary sites of oral cavity, oropharynx, hypopharynx, nasopharynx, paranasal sinus, nasal cavity, the orbit, thyroid and larynx. Pathology types like melanoma and sarcoma are also included.
    2. Prior conventional radiotherapy administered has been given for the disease (except melanoma).
    3. Bi-dimensionally measurable disease by MRI and/or CT scan and ≦ 12 cm in largest dimension.
    4. Age greater than 18 years and < 80 years, ECOG performance status ≦ 2
    5. WBC > 2.5 x109/L, neutrophil count >1.0 x109/L, platelet count >75x109/L, serum creatinine <1.25xULN.
    6. Informed consent signed.
    7. Tumor/normal tissue (T/N) ratio≧2.5 by BPA-PET scan.
  • For IG-IMRT:

    1. ECOG performance status ≦ 2
    2. No evidence of disease progression by physical examination or CT simulation.
    3. Nutrition support (feeding tube and/or IV fluid) already given for dysphagia, if present.
    4. Severity of mucositis and radiation dermatitis improved or downgrading, compared with those found in the 2nd or 3rd week after BNCT.

Exclusion Criteria:

  • For BNCT:

    1. Lymphoma or other tumor type that is expected to respond to cancer chemotherapy or to a dose of conventional radiation therapy that can be safely given.
    2. Patients who have an effective standard treatment option available.
    3. Distant metastasis outside of the head and neck region.
    4. Expecting life less than 3 months.
    5. A time interval less than 6 months from previous radiation therapy.
    6. Prior high-dose radiotherapy (Biological Effective Dose> 70 Gy/35 fractions) has been given for the present recurrent site within one year.
    7. Patients who had radiation myelitis or radiation necrosis of the brain/brain stem
    8. Time to recurrence from completion of prior surgery less than 6 months.
    9. Concurrent systemic cancer treatment including chemotherapy or target therapy (including cetuximab or EGFR oral tyrosine kinase inhibitor).
    10. Severe congestive heart failure or renal failure.
    11. Pregnancy
    12. Restless patients who were unable to lie or sit in a cast for 30-60 min.
    13. A cardiac pace-maker or an unremovable metal implant present in the head and neck region that will interfere with MRI-based dose-planning or tumor response evaluation.
  • For IG-IMRT:

    1. Any grade IV toxicity after BNCT.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02004795


Contacts
Layout table for location contacts
Contact: Ling-Wei Wang, MD 886-2-28757270 ext 308 lingweiw@gmail.com
Contact: Yi-Wei Chen, MD, PhD 886-2-28757270 ext 399 chenyw@vghtpe.gov.tw

Locations
Layout table for location information
Taiwan
Taipei Veterans General Hospital Recruiting
Taipei, Taiwan, 112
Principal Investigator: Ling-Wei Wang, MD         
Sponsors and Collaborators
Taipei Veterans General Hospital, Taiwan
National Tsing Hua University,Taiwan

Layout table for additonal information
Responsible Party: Taipei Veterans General Hospital, Taiwan
ClinicalTrials.gov Identifier: NCT02004795     History of Changes
Other Study ID Numbers: 2012-06-016A
First Posted: December 9, 2013    Key Record Dates
Last Update Posted: December 9, 2013
Last Verified: November 2013

Keywords provided by Taipei Veterans General Hospital, Taiwan:
Boron Neutron Capture Therapy
Image-guided intensity modulation radiotherapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Recurrence
Neoplasms by Site
Neoplasms
Disease Attributes
Pathologic Processes